Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50

Core Viewpoint - Exelixis, Inc. (NASDAQ:EXEL) is experiencing positive momentum in the stock market, with multiple analysts raising price targets and maintaining favorable ratings, driven by the potential of its drug Zanzalintinib [1][2][3] Group 1: Analyst Ratings and Price Targets - Morgan Stanley raised the price target for Exelixis to $50 from $46 while maintaining an Overweight rating [1][2] - Goldman Sachs initiated coverage with a Buy rating and a price target of $47, while Barclays assigned an Equal-Weight rating with a target of $40 [3] - Overall, Wall Street analysts have a consensus Buy rating for Exelixis, indicating an average share price upside potential of 11% [3] Group 2: Product Potential - Zanzalintinib is highlighted as a significant opportunity for Exelixis, with projected peak unadjusted sales of approximately $4.7 billion across various cancer types, including renal cell carcinoma, colorectal, and neuroendocrine tumors [2]